Multicenter randomized phase 2 trial of carfilzomib-based strategies in transplant-eligible multiple myeloma: long-term follow-up of FORTE

In the multicenter phase 2 FORTE trial in Italy, transplant-eligible multiple myeloma patients aged ≤ 65 years were randomized to (R1) carfilzomib-lenalidomide-dexamethasone followed by autologous stem cell transplantation (KRd-ASCT), twelve cycles of KRd (KRd12), or carfilzomib-cyclophosphamide-dexamethasone followed by ASCT (KCd-ASCT). Eligible patients were then randomized (R2) to maintenance with carfilzomib for two years plus lenalidomide until progression (KR) or lenalidomide alone until progression (R). With extended follow-up (median 99 months from R1 and 85 months from R2), KRd-ASCT significantly increased progression-free survival (PFS, median 98 months) versus KRd12 (median 70 months, HR 0.71; p=0.027) and KCd-ASCT (median 67 months; HR 0.66; p=0.006). A significant benefit in PFS2 was also observed versus both KRd12 (HR 0.65; p=0.02) and KCd-ASCT (HR 0.68; p=0.04) and in terms of overall survival versus KCd-ASCT (8-year OS rate (76% versus 68%; HR 0.65; p=0.04). KR maintenance significantly improved PFS versus R (HR 0.67; p=0.02), with a time-dependent effect persisting up to two years after carfilzomib discontinuation; no differences in PFS2/OS were observed. The cumulative incidence of second primary malignancies was 6%. The authors conclude that long-term follow-up confirms the effectiveness of KRd-ASCT and KR maintenance.